UCB Group
Allée de la Recherche, 60
Brussels
1070
Tel: (32-2) 559-99-99
Fax: (32-2) 559-99-00
Website: http://www.ucb.be/
192 articles about UCB Group
-
All of the recent problems have caused the company's largest shareholder to push for a sale.
-
Dermira and UCB Agree to End Collaboration Agreement for CIMZIA
11/7/2017
Dermira to transition development and commercialization responsibility for CIMZIA (certolizumab pegol) in psoriasis back to UCB.
-
Dermira, UCB Group Release: New CIMZIA (Certolizumab Pegol) Findings Presented At European Academy Of Dermatology And Venereology (EADV) Congress
9/14/2017
-
Dermira And UCB Group Release: New CIMZIA (Certolizumab Pegol) Data In Moderate-To-Severe Plaque Psoriasis And Psoriatic Arthritis Presented At American Academy of Dermatology 2017 Annual Meeting
3/6/2017
-
Dermira, UCB Group Release: Companies' Psoriasis Drug Wows In Phase III Study, Eyes Q3 Filing
1/19/2017
-
MC10 And UCB Group Complete Landmark Pharmaceutical / Technology Collaboration Evaluating Patient Monitoring In Parkinson’s
1/5/2017
-
Amgen And UCB Group Announce U.S. FDA Acceptance Of Biologics License Application For Romosozumab
9/27/2016
-
Amgen, UCB Group's Romosozumab Showed Significant Results in Phase III Study
9/19/2016
-
Syndax Expands Pipeline With Exclusive Worldwide License Agreement For UCB Group’s Colony Stimulating Factor 1 Receptor (CSF-1R) Antibody Program
7/6/2016
-
Amgen, UCB Group's Romosozumab Tops Teriparatide in Phase III Osteoporosis Study
4/4/2016
-
Amgen, UCB Group's Romosozumab Shines in Phase III Osteoporosis Trial
3/21/2016
-
U.S. FDA Approves UCB Group's New Epilepsy Treatment, BRIVIACT, For Patients With Partial-Onset Seizures
2/22/2016
-
Amgen, UCB Group's Osteoporosis Drug Comes Through in Late-Stage Study
2/22/2016
-
Merus Snags Three Cardiovascular Products from UCB Group in EUR 92 Million Deal
2/2/2016
-
UCB Group Divests U.S. Generics Unit For $1.53 Billion
11/7/2014
-
UCB Group Deploys IMS Health Nexxus Suite And Intelligent Cloud To Drive Commercial Productivity, Accelerate Time To Insight
10/22/2014
-
New Indication For VIMPAT® (Lacosamide): UCB Group's Anti-Epileptic Drug Approved By FDA As Monotherapy In The Treatment Of Patients With Partial-Onset Seizures
9/2/2014
-
UCB Group And Dermira Enter Into Strategic Collaboration In Dermatology To Broaden Patient Access To Cimzia® (Certolizumab Pegol)
7/3/2014
-
Beryllium Strengthens Collaboration With Key Partner, UCB Group
5/20/2014
-
Biopharma Learns From Marvel, UCB Group And Massachusetts Institute of Technology (MIT) Begin Real Life Search For "X-Men"
4/30/2014